| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Nubia Muñoz | Q25410302 |
| Silvia Franceschi | Q56417107 | ||
| Mireia Díaz | Q56438318 | ||
| Gary M Clifford | Q88381313 | ||
| P2093 | author name string | Luisa Lina Villa | |
| P2860 | cites work | Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial | Q28236008 |
| Against which human papillomavirus types shall we vaccinate and screen? The international perspective | Q28267023 | ||
| Human papillomavirus is a necessary cause of invasive cervical cancer worldwide | Q29617514 | ||
| Results of the first World Health Organization international collaborative study of detection of human papillomavirus DNA. | Q34430779 | ||
| Chapter 12: Human papillomavirus technologies. | Q35154951 | ||
| The clinical relevance of human papillomavirus testing: relationship between analytical and clinical sensitivity | Q35209576 | ||
| Molecular diagnosis of human papillomavirus (HPV) infections | Q36064303 | ||
| Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer | Q36128026 | ||
| Diagnosis and management of oncogenic cervical human papillomavirus infection | Q36166926 | ||
| Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis | Q36647828 | ||
| Thin-layer liquid-based cervical cytology and PCR for detecting and typing human papillomavirus DNA in Flemish women. | Q36649083 | ||
| Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis | Q36670753 | ||
| Reliable high risk HPV DNA testing by polymerase chain reaction: an intermethod and intramethod comparison | Q37239453 | ||
| Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities | Q44113435 | ||
| Human papillomavirus type 16 and immune status in human immunodeficiency virus-seropositive women. | Q45722582 | ||
| Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis | Q46926059 | ||
| The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. | Q51968734 | ||
| Re: A Study of the Impact of Adding HPV Types to Cervical Cancer Screening and Triage Tests | Q58281465 | ||
| Distribution of human papillomavirus types in cervicovaginal washings from women evaluated in a sexually transmitted diseases clinic | Q78614346 | ||
| Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica | Q81714676 | ||
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | S3/26-34 | |
| P577 | publication date | 2006-06-02 | |
| P1433 | published in | Vaccine | Q7907941 |
| P1476 | title | Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases | |
| P478 | volume | 24 Suppl 3 |
| Q35196119 | A chimeric 18L1-45RG1 virus-like particle vaccine cross-protects against oncogenic alpha-7 human papillomavirus types |
| Q36563683 | A fully integrated paperfluidic molecular diagnostic chip for the extraction, amplification, and detection of nucleic acids from clinical samples |
| Q37152248 | A meta-analysis of human papillomavirus type-distribution in women from South Asia: implications for vaccination |
| Q40129472 | A novel trivalent HPV 16/18/58 vaccine with anti-HPV 16 and 18 neutralizing antibody responses comparable to those induced by the Gardasil quadrivalent vaccine in rhesus macaque model |
| Q37226168 | A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention |
| Q26741909 | A review of the infection-associated cancers in North African countries |
| Q44408279 | Adherence to cervical screening in the era of human papillomavirus vaccination: how low is too low? |
| Q34278466 | Adherence to conservative management recommendations for abnormal pap test results in adolescents |
| Q39122219 | An exploration of human papillomavirus-related cervical cancer prevention experiences among college women: a descriptive qualitative approach |
| Q38946815 | Analysis of human papillomavirus E7 protein status in C-33A cervical cancer cells. |
| Q36957989 | Analysis of human papillomavirus type 16 (HPV16) DNA load and physical state for identification of HPV16-infected women with high-grade lesions or cervical carcinoma. |
| Q43096878 | Analysis of modified human papillomavirus type 16 L1 capsomeres: the ability to assemble into larger particles correlates with higher immunogenicity |
| Q93125739 | Analytical Evaluation of the Human Papillomavirus HPV DNA Array E1-Based Genotyping Assay |
| Q94086327 | Approuvez-vous les 300 M $ pour la vaccination contre le VPH?: OUI |
| Q26783973 | Are the Two Human Papillomavirus Vaccines Really Similar? A Systematic Review of Available Evidence: Efficacy of the Two Vaccines against HPV |
| Q35117498 | Aspects of prophylactic vaccination against cervical cancer and other human papillomavirus-related cancers in developing countries |
| Q41660112 | Assessing Knowledge and Attitudes towards Cervical Cancer Screening among Rural Women in Eastern China. |
| Q44046271 | Assessing the introduction of universal human papillomavirus vaccination for preadolescent girls in The Netherlands |
| Q40709466 | Assessment of the frequency of genetic alterations (LOH/MSI) in patients with intraepithelial cervical lesions with HPV infection: a pilot study |
| Q34187046 | Association between toll-like receptor expression and human papillomavirus type 16 persistence |
| Q37848816 | Association of HPV infection and Chlamydia trachomatis seropositivity in cases of cervical neoplasia in Midwest Brazil. |
| Q36319807 | Associations of Human Papillomavirus (HPV) genotypes with high-grade cervical neoplasia (CIN2+) in a cohort of women living with HIV in Burkina Faso and South Africa |
| Q26784314 | Autophagy knocked down by high-risk HPV infection and uterine cervical carcinogenesis |
| Q36330260 | Awareness and acceptance of human papillomavirus vaccination among health sciences students in Malaysia |
| Q47239245 | Awareness of and willingness to be vaccinated by human papillomavirus vaccine among junior middle school students in Jinan, China. |
| Q40025709 | Benefits, cost requirements and cost-effectiveness of the HPV16,18 vaccine for cervical cancer prevention in developing countries: policy implications |
| Q92424534 | Burden and genotype distribution of high-risk Human Papillomavirus infection and cervical cytology abnormalities at selected obstetrics and gynecology clinics of Addis Ababa, Ethiopia |
| Q46302480 | Burden and trends of type-specific human papillomavirus infections and related diseases in the Asia Pacific region |
| Q37306129 | Burden and trends of type-specific human papillomavirus infections and related diseases in the latin america and Caribbean region |
| Q92131918 | CIN2+ detection of the HPV DNA Array genotyping assay in comparison with the Cobas 4800 HPV test and cytology |
| Q36109828 | Can human papillomavirus (HPV) genotyping classify non-16/18 high-risk HPV infection by risk stratification? |
| Q37312127 | Cancer registries and monitoring the impact of prophylactic human papillomavirus vaccines: the potential role |
| Q41139348 | Carcinogenic ability quantification of human papilloma virus subtypes in eastern China |
| Q93366821 | Cervical cancer screening by molecular Pap-transformation of gynecologic cytology |
| Q93038273 | Cervical cancer screening uptake and correlates among HIV-infected women: a cross-sectional survey in Côte d'Ivoire, West Africa |
| Q36452612 | Cervical human papillomavirus (HPV) infection in South African women: implications for HPV screening and vaccine strategies |
| Q28730416 | Cervical screening within HIV care: findings from an HIV-positive cohort in Ukraine |
| Q36632749 | Characterisation of human papillomavirus (HPV) genotypes in the Azorean population, Terceira island. |
| Q42278244 | Characterization of human papillomavirus by capillary isoelectric focusing with whole-column imaging detection |
| Q37845180 | Chlamydia trachomatis infection and human papillomavirus in women with cervical neoplasia in Pernambuco-Brazil. |
| Q58692131 | Clearance of Type-Specific, Low-Risk, and High-Risk Cervical Human Papillomavirus Infections in HIV-Negative and HIV-Positive Women |
| Q40854884 | Clinical Performance of APTIMA Human Papillomavirus (HPV) 16 18/45 mRNA Genotyping Testing for the Detection of Cervical Intraepithelial Neoplasia 3 (CIN3) or Cancer in a Select Group of Chinese Women |
| Q56787289 | Clinical trial experience with prophylactic HPV 6/11/16/18 VLP vaccine in young women from the Asia-Pacific region |
| Q34076719 | Co-infection with HPV types from the same species provides natural cross-protection from progression to cervical cancer. |
| Q42264464 | Colorimetric detection of human papilloma virus by double isothermal amplification. |
| Q34938697 | Comparing human papillomavirus prevalences in women with normal cytology or invasive cervical cancer to rank genotypes according to their oncogenic potential: a meta-analysis of observational studies |
| Q53301243 | Comparison of HPV genotyping by type-specific PCR and sequencing. |
| Q48542136 | Conservative management of CIN2: National Audit of British Society for Colposcopy and Cervical Pathology members' opinion |
| Q34193290 | Construction of a full transcription map of human papillomavirus type 18 during productive viral infection |
| Q34365197 | Correlates of human papillomavirus vaccination rates in low-income, minority adolescents: a multicenter study |
| Q24655328 | Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States |
| Q37273434 | Cost effectiveness of human papillomavirus-16/18 genotyping in cervical cancer screening |
| Q51148505 | Cost-effectiveness of 12- and 15-year-old girls' human papillomavirus 16/18 population-based vaccination programmes in Lithuania. |
| Q37425356 | Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in women older than 30 years in the United States |
| Q51862683 | Cost-effectiveness of vaccination against cervical cancer: a multi-regional analysis assessing the impact of vaccine characteristics and alternative vaccination scenarios. |
| Q28079776 | Current global status & impact of human papillomavirus vaccination: Implications for India |
| Q30276138 | Cutaneous beta human papillomaviruses and the development of male external genital lesions: A case-control study nested within the HIM Study |
| Q30409315 | Cutaneous human papillomavirus types detected on the surface of male external genital lesions: a case series within the HPV Infection in Men Study |
| Q29353767 | Determinants of HPV vaccination intentions among Dutch girls and their mothers: a cross-sectional study |
| Q36567611 | Developing Michigan Cancer Foundation 7 Cells with Stable Expression of E7 Gene of Human Papillomavirus Type 16. |
| Q38023288 | Differences in human papillomavirus type distribution in high-grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe |
| Q58426181 | Distinct distribution of HPV types among cancer-free Afro-Caribbean women from Tobago |
| Q57089348 | Distribution of human papillomavirus genotypes in cervical intraepithelial neoplasia and invasive cervical cancer in Canada |
| Q37034967 | Divergent viral presentation among human tumors and adjacent normal tissues. |
| Q43092329 | Do you approve of spending $300 million on HPV vaccination?: yes. |
| Q53221107 | Dysregulated microRNAs involved in the progression of cervical neoplasm. |
| Q37188108 | Early detection of cervical carcinomas: finding an overall approach |
| Q41051528 | Effectiveness of human papillomavirus vaccine against incident and persistent infections among young girls: Results from a longitudinal Dutch cohort study |
| Q81339726 | Effects of quadrivalent human papillomavirus vaccination |
| Q35427518 | Efficacy of commercially available vaccines against HPV infection in women: a systematic review and meta-analysis |
| Q34291189 | Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical intraepithelial neoplasia and cervical infection in young Japanese women. |
| Q34199773 | Efficacy of vaccination against HPV infections to prevent cervical cancer in France: present assessment and pathways to improve vaccination policies |
| Q37548432 | English proficiency, knowledge, and receipt of HPV vaccine in Vietnamese-American women |
| Q56793030 | Estimated acceptance of HPV vaccination among Italian women aged 18–26 years |
| Q33467330 | Estimating progression rates for human papillomavirus infection from epidemiological data |
| Q37622268 | Evaluation of the Oncogenic Human Papillomavirus DNA Test with Liquid-Based Cytology in Primary Cervical Cancer Screening and the Importance of the ASC/SIL Ratio: A Belgian Study. |
| Q45289974 | Exploring the cost-effectiveness of HPV vaccination in Vietnam: insights for evidence-based cervical cancer prevention policy |
| Q37693170 | Exposé of misleading claims that male circumcision will increase HIV infections in Africa |
| Q35164128 | Expression of nucleic acid-sensing Toll-like receptors predicts HPV16 clearance associated with an E6-directed cell-mediated response |
| Q38380284 | Four-year persistence of type-specific immunity after quadrivalent human papillomavirus vaccination in HIV-infected children: Effect of a fourth dose of vaccine |
| Q38971877 | Genital Human Papillomavirus Infection in Indian HIV-Seropositive Men Who Have Sex With Men. |
| Q37357927 | Genotype distribution of cervical human papillomavirus DNA in women with cervical lesions in Bioko, Equatorial Guinea. |
| Q34483573 | Genotype distribution of human papillomavirus (HPV) in histological sections of cervical intraepithelial neoplasia and invasive cervical carcinoma in Madrid, Spain |
| Q37484683 | Grading the severity of cervical neoplasia based on combined histopathology, cytopathology, and HPV genotype distribution among 1,700 women referred to colposcopy in Oklahoma |
| Q37066141 | Guidelines of the Italian Society for Virology on HPV testing and vaccination for cervical cancer prevention |
| Q38944679 | HIV-associated malignancies in sub-Saharan Africa: progress, challenges, and opportunities |
| Q53176137 | HPV DNA methylation at the early promoter and E1/E2 integrity: A comparison between HPV16, HPV18 and HPV45 in cervical cancer. |
| Q38621813 | HPV Genotype-Specific Persistence and Potential Risk Factors Among Korean Women: Results from a 2-Year Follow-up Study. |
| Q36976268 | HPV Vaccines: today and in the Future |
| Q37289555 | HPV awareness, knowledge and attitudes among older African-American women. |
| Q34485433 | HPV genotypes and associated cervical cytological abnormalities in women from the Pearl River Delta region of Guangdong province, China: a cross-sectional study |
| Q91344525 | HPV infection and the genital cytokine milieu in women at high risk of HIV acquisition |
| Q40009620 | HPV information needs, educational messages and channel of delivery preferences: views from developing country with multiethnic populations |
| Q33568522 | HPV prevalence in Colombian women with cervical cancer: implications for vaccination in a developing country |
| Q37315939 | HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women |
| Q34745786 | HPV type-specific prevalence using a urine assay in unvaccinated male and female 11- to 18-year olds in Scotland |
| Q45105791 | HPV vaccination and colposcopy workload of screening programmes |
| Q54744832 | HPV vaccination: an opportunity for good and the potential for harm. |
| Q42242723 | HPV16 E6*II gene expression in intraepithelial cervical lesions as an indicator of neoplastic grade: a pilot study |
| Q34824304 | Health and economic implications of HPV vaccination in the United States |
| Q38873922 | Health systems and immunization financing for human papillomavirus vaccine introduction in low-resource settings |
| Q47356408 | Healthcare spending in the case of a HPV16/18 population-wide vaccination programme |
| Q84341088 | High-risk HPV detection and concurrent HPV 16 and 18 typing with Abbott RealTime High Risk HPV test |
| Q37089452 | High-risk and multiple human papillomavirus (HPV) infections in cancer-free Jamaican women |
| Q44186333 | High-risk human papilloma virus prevalence and its relation with abnormal cervical cytology among Turkish women |
| Q39229942 | High-risk human papillomavirus types in HIV-infected and HIV-uninfected young women in KwaZulu-Natal, South Africa: implications for vaccination |
| Q80167962 | How much cervical cancer in Australia is vaccine preventable? A meta-analysis |
| Q47558350 | Human Papilloma Viruses and Their Genotype Distribution in Women with High Socioeconomic Status in Central Anatolia, Turkey: A Pilot Study. |
| Q42283714 | Human papillomavirus (HPV) infection and vaccines: knowledge, attitude and perception among female students at the University of Lagos, Lagos, Nigeria |
| Q24657891 | Human papillomavirus and HPV vaccines: a review |
| Q54023273 | Human papillomavirus and cervical cancer |
| Q27023127 | Human papillomavirus and cervical cancer: biomarkers for improved prevention efforts |
| Q36786011 | Human papillomavirus and vaccination: knowledge, attitudes, and behavioural intention in adolescents and young women in Italy |
| Q33794306 | Human papillomavirus detection in women with and without human immunodeficiency virus infection in Colombia |
| Q51426652 | Human papillomavirus genotype detection and viral load in paired genital and urine samples from both females and males. |
| Q36358126 | Human papillomavirus genotypes among women with or without HIV infection: an epidemiological study of Moroccan women from the Souss area |
| Q36466809 | Human papillomavirus genotypes distribution among Gabonese women with normal cytology and cervical abnormalities |
| Q37178382 | Human papillomavirus genotypes distribution in cervical cancer cases in Gabon |
| Q57211446 | Human papillomavirus infection and cervical cancer prevention in Japan and Korea |
| Q37159208 | Human papillomavirus infection in women attended at a cervical cancer screening service in Natal, Brazil |
| Q36817148 | Human papillomavirus therapeutic vaccines in head and neck tumors |
| Q36086661 | Human papillomavirus type 16 genetic variants: phylogeny and classification based on E6 and LCR. |
| Q39958046 | Human papillomavirus type 45 E7 is a transforming protein inducing retinoblastoma protein degradation and anchorage-independent cell cycle progression. |
| Q40114649 | Human papillomavirus type-distribution in the cervix of Chinese women: a meta-analysis |
| Q34959801 | Human papillomavirus types by age in cervical cancer precursors: predominance of human papillomavirus 16 in young women |
| Q82710054 | Human papillomavirus vaccine for children and adolescents |
| Q40239266 | Human papillomavirus vaccine update |
| Q35944623 | Human papillomavirus vaccines launch a new era in cervical cancer prevention |
| Q34140890 | Human papillomavirus-type distribution in women with and without cervical neoplasia in north India |
| Q37135018 | Identification of potential missed opportunities for human papillomavirus (HPV) vaccination in women referred to an academic colposcopy clinic for evaluation of abnormal cervical cytology |
| Q31159398 | Immunogenicity of a trivalent human papillomavirus L1 DNA-encapsidated, non-replicable baculovirus nanovaccine |
| Q36168769 | Impact of human papilloma virus vaccination on adolescent knowledge, perception of sexual risk and need for safer sexual behaviors in Bali, Indonesia |
| Q43655015 | Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women |
| Q81689876 | Impact of vaccination with Cervarix (trade mark) on subsequent HPV-16/18 infection and cervical disease in women 15-25 years of age |
| Q42737373 | Improved Antiviral Activity of a Polyamide Against High-Risk Human Papillomavirus Via N-Terminal Guanidinium Substitution |
| Q40126932 | Improving the performance of reflex Human Papilloma Virus (HPV) testing in triaging women with atypical squamous cells of undetermined significance (ASCUS): A restrospective study in a tertiary hospital in United Arab Emirates (UAE). |
| Q48043820 | Infection with high-risk HPV types among female sex workers in northern Vietnam |
| Q35028233 | Knowledge about human papillomavirus and the human papillomavirus vaccine in Belgian students |
| Q92312026 | Knowledge, Attitude, and Barriers Towards Human Papillomavirus (HPV) Vaccination Among Youths of Karachi, Pakistan |
| Q33568901 | Knowledge, attitude & practice on human papillomavirus vaccination: A cross-sectional study among healthcare providers |
| Q56793023 | Knowledge, attitude and practice in primary and secondary cervical cancer prevention among young adult Italian women |
| Q59352974 | Knowledge, understanding, attitude, perception and views on HPV infection and vaccination among health care students and professionals in Malaysia |
| Q42262387 | Large scale study of HPV genotypes in cervical cancer and different cytological cervical specimens in Thailand |
| Q94272324 | Le vaccin contre le virus du papillome humain pour les enfants et les adolescents |
| Q33834332 | Long-term follow-up of cervical disease in women screened by cytology and HPV testing: results from the HART study |
| Q48312293 | Long‐term cytological and histological outcomes in women managed with loop excision treatment under local anaesthetic for high‐grade cervical intraepithelial neoplasia |
| Q41476538 | MBL2 polymorphisms in women with atypical squamous cells of undetermined significance. |
| Q33378841 | Mathematical models of cervical cancer prevention in the Asia Pacific region |
| Q34777452 | Measuring effectiveness of the cervical cancer vaccine in an Australian setting (the VACCINE study) |
| Q42197971 | Meta-analysis of type-specific human papillomavirus prevalence in Iranian women with normal cytology, precancerous cervical lesions and invasive cervical cancer: Implications for screening and vaccination |
| Q30573204 | Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada |
| Q37116753 | Modified general primer PCR system for sensitive detection of multiple types of oncogenic human papillomavirus |
| Q33349196 | Molecular epidemiology and pathogenic potential of underdiagnosed human papillomavirus types |
| Q36140447 | Nationwide Survey of Knowledge and Health Beliefs regarding Human Papillomavirus among HPV-Vaccinated Female Students in Malaysia |
| Q37604535 | Natural history of anal human papillomavirus infection in heterosexual women and risks associated with persistence |
| Q46648097 | Natural seroconversion to high-risk human papillomaviruses (hrHPVs) is not protective against related HPV genotypes |
| Q33394011 | New paradigms in cervical cancer prevention: opportunities and risks |
| Q33963645 | Nucleic acid sequence-based amplification assay for human papillomavirus mRNA detection and typing: evidence for DNA amplification. |
| Q37232373 | Part II: Cancer in Indigenous Africans--causes and control. |
| Q59397134 | Pediatrician knowledge and attitudes regarding human papillomavirus disease and its prevention |
| Q50051634 | Persistence of memory B-cell and T-cell responses to the quadrivalent HPV vaccine in HIV-infected children |
| Q35832915 | Physical state and viral load as predictive biomarkersfor persistence and progression of HPV16-positive cervical lesions: results from a population based long-term prospective cohort study |
| Q93070827 | Pleurotus ferulae polysaccharides improve the antitumor efficacy of therapeutic human papillomavirus dendritic cell-based vaccine |
| Q37777968 | Position paper--HPV and the primary prevention of cancer; improving vaccine uptake by paediatricians |
| Q33708098 | Predicted impact of vaccination against human papillomavirus 16/18 on cancer incidence and cervical abnormalities in women aged 20-29 in the UK. |
| Q52727412 | Prediction of cervical cancer incidence in England, UK, up to 2040, under four scenarios: a modelling study. |
| Q30376834 | Prevalence and risk factors associated with sexually transmitted infections (STIs) among women of reproductive age in Swaziland. |
| Q36346755 | Prevalence and risk factors for HPV in HIV-positive young women receiving their first HPV vaccination |
| Q54265480 | Prevalence and type distribution of human papillomavirus (HPV) in Malaysian women with and without cervical cancer: an updated estimate. |
| Q37435623 | Prevalence of Human Papilloma Virus Infection in Young Primiparous Women During Postpartum Period: Study from a Tertiary Care Center in Northern India |
| Q36257446 | Prevalence of and Associated Risk Factors for High Risk Human Papillomavirus among Sexually Active Women, Swaziland |
| Q35413976 | Prevalence of human papillomavirus genotypes among African women with normal cervical cytology and neoplasia: a systematic review and meta-analysis |
| Q30577846 | Prevalence of human papillomavirus in women attending cervical screening in the UK and Ireland: new data from northern Ireland and a systematic review and meta-analysis |
| Q49281213 | Prevalence of human papillomavirus infection among women from quilombo communities in northeastern Brazil. |
| Q34069384 | Prevalence of human papillomavirus infection and phylogenetic analysis of HPV-16 E6 variants among infected women from Northern Brazil. |
| Q37403541 | Prevalence of human papillomavirus type 58 in women with or without cervical lesions in northeast Brazil |
| Q47764270 | Prevalence of human papillomavirus types in cervical lesions from women in rural Western India |
| Q85097331 | Prevalence of low‐risk and high‐risk types of human papillomavirus and other risk factors for HPV infection in Germany within different age groups in women up to 30 years of age: An epidemiological observational study |
| Q36046789 | Prevalence, Predictors, and Same Day Treatment of Positive VIA Enhanced by Digital Cervicography and Histopathology Results in a Cervical Cancer Prevention Program in Cameroon |
| Q33761437 | Prevalence, distribution and correlates of endocervical human papillomavirus types in Brazilian women. |
| Q34272071 | Prevention of cervical, vaginal, and vulval cancers: role of the quadrivalent human papillomavirus (6, 11, 16, 18) recombinant vaccine |
| Q35984558 | Prophylactic HPV vaccines |
| Q36610447 | Prophylactic HPV vaccines: prospects for eliminating ano-genital cancer |
| Q33292779 | Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials |
| Q37349077 | Quadrivalent HPV vaccine effectiveness against high-grade cervical lesions by age at vaccination: A population-based study |
| Q38097614 | Race, ethnicity and income as factors for HPV vaccine acceptance and use. |
| Q39890236 | Refining HPV 16 L1 purification from E. coli: reducing endotoxin contaminations and their impact on immunogenicity |
| Q35219098 | Regulation of cellular miRNA expression by human papillomaviruses |
| Q35538088 | Remodeling of extracellular matrix by normal and tumor-associated fibroblasts promotes cervical cancer progression. |
| Q38253253 | Site of infections associated with human papillomavirus |
| Q37141074 | Spousal migration and human papillomavirus infection among women in rural western Nepal. |
| Q36190228 | Study-based evaluation of the Abbott RealTime High Risk HPV test in comparison to the HC2 HR HPV test in women aged ≥30 years using residual LBC ThinPrep specimens. |
| Q40125322 | The ATHENA HPV study underrepresents "other" high-risk HPV genotypes when compared with a diverse New York City population |
| Q28544832 | The E6AP binding pocket of the HPV16 E6 oncoprotein provides a docking site for a small inhibitory peptide unrelated to E6AP, indicating druggability of E6 |
| Q57028715 | The Impact of HPV as an Etiological Factor in Gynecological and Oropharyngeal Cancer |
| Q33609914 | The antiviral restriction factors IFITM1, 2 and 3 do not inhibit infection of human papillomavirus, cytomegalovirus and adenovirus |
| Q40918866 | The association of HPV genotype with the regression, persistence or progression of low-grade squamous intraepithelial lesions. |
| Q38239507 | The burden of HPV-associated anogenital cancers |
| Q34259805 | The choice of resin-bound ligand affects the structure and immunogenicity of column-purified human papillomavirus type 16 virus-like particles |
| Q50857612 | The combination of Pleurotus ferulae water extract and CpG-ODN enhances the immune responses and antitumor efficacy of HPV peptides pulsed dendritic cell-based vaccine. |
| Q36610328 | The contribution of HPV18 to cervical cancer is underestimated using high-grade CIN as a measure of screening efficiency |
| Q33638499 | The human papillomavirus type 58 E7 oncoprotein modulates cell cycle regulatory proteins and abrogates cell cycle checkpoints |
| Q36871265 | The human papillomavirus vaccine: The promise of cervical cancer prevention |
| Q47596026 | The impact of human papillomavirus (HPV) types 6, 11 in women with genital warts |
| Q37250972 | The landscape of viral expression and host gene fusion and adaptation in human cancer |
| Q45354037 | The production and immunogenicity of human papillomavirus type 58 virus-like particles produced in Saccharomyces cerevisiae |
| Q42202035 | The three most common human papillomavirus oncogenic types and their integration state in Thai women with cervical precancerous lesions and carcinomas |
| Q36611500 | The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting |
| Q38420261 | Time trends of human papillomavirus type distribution in Italian women with cervical intraepithelial neoplasia (CIN). |
| Q36793117 | Translational mini-review series on vaccines: Monitoring of human papillomavirus vaccination |
| Q38635196 | Type-specific human papillomavirus prevalence in cervical intraepithelial neoplasia and cancer in Iran. |
| Q30712681 | Type-specific prevalence of high-risk human papillomavirus by cervical cytology and age: Data from the health check-ups of 7,014 Korean women |
| Q34121746 | Updated guidelines for papanicolaou tests, colposcopy, and human papillomavirus testing in adolescents |
| Q35036066 | Updating the PGMY primers and probes for improved detection of HPV68a: validation of version 2 of the PGMY-CHUV assay |
| Q43210191 | Vaccination and screening programs: harmonizing prevention strategies for HPV-related diseases |
| Q35591138 | Vaccination recommendations for Germany |
| Q47653424 | What cervical screening is appropriate for women who have been vaccinated against high risk HPV? A simulation study |
| Q33858647 | When do sexual partnerships need to be accounted for in transmission models of human papillomavirus? |
| Q41277821 | Why are U.S. girls getting meningococcal but not human papilloma virus vaccines? Comparison of factors associated with human papilloma virus and meningococcal vaccination among adolescent girls 2008 to 2012. |
| Q33578796 | Why do low-income minority parents choose human papillomavirus vaccination for their daughters? |
Search more.